Hiroaki Kanemura, Toshihide Yokoyama, Ryu Nakajima, Atsushi Nakamura, Hiroaki Kuroda, Yoshitaka Kitamura, Hiroyasu Shoda, Nobuaki Mamesaya, Yoshihiro Miyata, Tatsuro Okamoto, Kyoichi Okishio, Masahide Oki, Yuichi Sakairi, Toyofumi Fengshi Chen-Yoshikawa, Tadashi Aoki, Tatsuo Ohira, Isao Matsumoto, Kiyonobu Ueno, Takuro Miyazaki, Haruhisa Matsuguma, Hideoki Yokouchi, Tomoyuki Otani, Akihiko Ito, Kazuko Sakai, Yasutaka Chiba, Kazuto Nishio, Nobuyuki Yamamoto, Isamu Okamoto, Kazuhiko Nakagawa, Masayuki Takeda
INTRODUCTION: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence after adjuvant chemotherapy or who are likely to benefit from postoperative immunotherapy have remained unclear. METHODS: This biomarker study (WJOG12219LTR) was designed to evaluate cancer stem cell markers (CD44 and CD133), programmed death-ligand 1 (PD-L1) expression on tumor cells, CD8 expression on tumor-infiltrating lymphocytes, and tumor mutation burden in completely resected stage II to IIIA NSCLC with the use of archived DNA and tissue samples from the prospective WJOG4107 trial...
April 2024: JTO clinical and research reports